Tumours elicit an immune attack that can stifle their growth, but they can also recruit inflammatory immune cells that suppress this response. A new study identifies distinct immune subtypes of triple-negative breast cancer with two different inflammatory cell types: macrophages or neutrophils. The immune subtype dictates the response to immunotherapy